All News

24 June 2011

iCo Therapeutics Executes Bertilimumab License with Immune PharmaceuticalsAntibodies

24 June 2011

Baxter Receives Positive Opinion for IVIG Therapy in Europe for Treatment of Multifocal Motor NeuropathyAntibodies

24 June 2011

Genmab Announces Zalutumumab UpdateAntibodies

24 June 2011

Amgen Receives Positive CHMP Opinion for Vectibix (Panitumumab) in Combination With ChemotherapyAntibodies

22 June 2011

European Commission Approves Inclusion of Anti-JC Virus Antibody Status as a PML Risk Factor in TYSABRI LabelingAntibodies

21 June 2011

Abbott and Biotest Announce Global Agreement to Develop and Commercialize Novel Antibody for Autoimmune DiseasesAntibodies

21 June 2011

Compugen Announces Initial Validation of Additional B7/CD28 Protein Family Based Product CandidateAntibodies

20 June 2011

Alexion Initiates Clinical Trial of Eculizumab as a Potential Treatment for Patients with STEC-HUS in Expanded Response to EHEC Crisis in GermanyAntibodies

20 June 2011

Alder Biopharmaceuticals to Receive $15 Million Milestone Payment from Bristol-Myers Squibb for Initiation of Phase 2b Clinical Trial in Rheumatoid Arthritis of ALD518/BMS-945429 Antibody Therapeutic Against IL-6Antibodies

17 June 2011

Immune System Therapeutics Limited Drug Shows Positive Response in Patients with Multiple Myeloma Blood CancerAntibodies

17 June 2011

Regeneron Announces EYLEA (aflibercept ophthalmic solution) Receives Unanimous Recommendation for Approval for Treatment of Wet AMD from FDA Advisory CommitteeAntibodies

16 June 2011

FDA approves Nulojix for kidney transplant patientsAntibodies

16 June 2011

Seattle Genetics Announces FDA Advisory Committee to Review Brentuximab Vedotin for the Treatment of Relapsed or Refractory Hodgkin Lymphoma and Systemic ALCLAntibodies

16 June 2011

Phase II Study Evaluates Clinical Benefit of Combining REVLIMID with rituximab to Enhance Anti-Cancer Activity in Mantle Cell LymphomaAntibodies

15 June 2011

Peregrine Reports Promising 12.4 Month Overall Survival Data From Phase II Trial in Non-Small Cell Lung CancerAntibodies

15 June 2011

ImmunoGen, Inc. Earns Milestone with BAY 94-9343 IND SubmissionAntibodies

13 June 2011

Researchers Present Final Data from Phase 2 Studies of Soliris (eculizumab) in Patients with aHUSAntibodies

13 June 2011

Merck and Hanwha Chemical Corporation Establish Global Strategic Collaboration to Develop and Commercialize Biosimilar CandidateAntibodies

10 June 2011

Symphogen Presents Preliminary Results from Phase 2 Clinical Trial with Rozrolimupab at the Annual European Hematology AssociationAntibodies

10 June 2011

Study Demonstrates Micromet’s Blinatumomab Produces High Single-Agent Activity in Patients with Relapsed Acute Lymphoblastic LeukemiaAntibodies

10 June 2011

Millennium and Seattle Genetics Present Clinical Data on ADCETRIS (Brentuximab Vedotin) in Systemic ALCL at EHA Annual MeetingAntibodies

9 June 2011

XOMA Announces Phase 2a Six-Month Top Line Trial Results Support Safety and Biological ActivityAntibodies

9 June 2011

Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of Second Antibody-Drug Conjugate (ADC) Under Existing CollaborationAntibodies

7 June 2011

Emergent BioSolutions Acquires Late-Stage Monoclonal Antibody Cancer Therapy from TenX BioPharmaAntibodies

7 June 2011

VEGF Trap-Eye Submitted for EU Marketing Authorization for Treatment of Wet Age-Related Macular DegenerationAntibodies

7 June 2011

Immunomedics Reports Final Survival Data With Yttrium-90-Labeled Clivatuzumab Tetraxetan and Low-Dose Gemcitabine in Advanced Pancreatic CancerAntibodies

7 June 2011

Quest PharmaTech Provides Oregovomab Chemo Immunotherapy Clinical Trial and other Corporate UpdatesAntibodies

6 June 2011

Oxford BioMedica Announces 5T4 Antibody Research Collaboration with ImaginAbAntibodies

6 June 2011

Immunomedics Reports First Clinical Results of New Antibody-Directed Radiation Therapy for Colorectal CancerAntibodies

6 June 2011

Seattle Genetics Presents SGN-75 Clinical Data at ASCO Annual MeetingAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Ranibizumab (Lucentis) Biosimilars Pipeline Review

Folate Receptor alpha (FRα) Targeted Therapy Pipeline Review

RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

GPRC5D-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

Blockbuster Biologics 2018: Sales of Recombinant Therapeutic Antibodies & Proteins

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

Aflibercept (Eylea) Biosimilars Pipeline Review

Claudin 6: A target opportunity to develop effector-enhanced drug modalities

Antibody Target, Technology & Pipeline Database: 1-Year Subscription

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis